Santen Pharmaceutical is a global pharmaceutical company based in Miami, FL, specializing in ophthalmology. With a history of over a century, Santen is committed to enhancing patients' satisfaction and product safety through their medium-term management plan, Santen 2030. They focus on research and development to address untreated patients and offer innovative solutions in the field of ophthalmology. Santen's dedication to sustainability is evident through their efforts in social access to healthcare, environmental initiatives, and inclusive society promotion.
In 2016, Santen acquired InnFocus, Inc., a company that specializes in the development of biomaterials for glaucoma surgery. InnFocus has pioneered the use of SIBS, a degradation-resistant biostable polymer, in the creation of implantable products. SIBS has been successfully used in cardiology to develop stents that prevent restenosis without the risk of biodegradation. Building on this success, InnFocus has focused on incorporating SIBS into surgical devices for glaucoma treatment, addressing unmet needs in the field. Through their dedication to innovation and patient care, Santen and InnFocus are at the forefront of advancements in ophthalmology.
Generated from the website